Review article

New standards in the chemotherapy of breast cancer

Tanja Čufer ; Institute of Oncology, Ljubljana, Slovenia

Abstract

During the last few years progress in breast cancer (BC) chemotherapy (CT) was made through the incorporation of taxanes into treatment schedules, the manipulation of dose-size and dose-density of our most active cytotoxic agents and recently, through the incorporation of trastuzumab into treatment schedules for all stages of BC. Further progress is foreseen by incorporating additional molecularly targeted therapies into treatment schemas and by improved molecular classification of disease based on gene expression profiles and signatures that might predict for prognosis and response to chemotherapy. In this review, the main findings related to these topics are summarized, currently recommended chemotherapy treatment options are discussed, and future directions of research are alighted.

Keywords

breast cancer; chemotherapy; molecularly targeted therapies

Hrčak ID:

281504

URI

https://hrcak.srce.hr/281504

Publication date:

7.12.2006.

Article data in other languages: croatian

Visits: 736 *